FTC Navigating Regulatory Restraints As Bill To Restore Monetary Relief Authority Faces Challenges
Congressional Republicans and biopharma stakeholders support legislation clarifying the Federal Trade Commission’s authority to assess monetary penalties but argue the House legislation needs guardrails.
You may also be interested in...
Agency staff has more freedom to launch investigations under resolutions approved at Commission’s first meeting under new chair. Mergers and rebate walls expected to be major priorities.
During subcommittee markup, Republican members offered amendments to limit FTC’s ability to seek monetary relief for consumers. Measure has the ‘potential to be a legacy bill,’ ranking member says, indicating it may clear Congress.
AbbVie and FTC both see wins and setbacks in Third Circuit ruling on case involving reverse-payment patent settlement with Teva.